VERTIS CV Trial: The SGLT-2 inhibitors are the next generation drugs for type 2 diabetes as well as patients with heart failure. We have seen…
The SGLT-2 inhibitors were initially developed for diabetes but eventually noted to have significant effects on outcomes in patients with heart failure in addition to…
Multiple small trials in the past have shown benefits of liberal transfusion strategy in patients having active MI. However, a large size trial was lacking.…
In patients with nonvalvular afib, rate control was considered to be no different than rhythm control based on the AFFIRM trial results that was published…
EXPLORER HCM Trial Summary: Mavacamten is a novel cardiac-specific myosin ATPase inhibitor. It specifically reduces excessive cross-bridging with actin, which is associated with pathological hypercontractility…
PADIT Trial Summary The PADIT Trial (Prevention of Arrhythmia Device Infection Trial) was a cluster randomized crossover trial that was designed to assess the efficacy…
WRAP-IT trial summary WRAP-IT trial is a multicenter, randomized, controlled, prospective, single-blind trial that was published in the New England Journal of medicine in 2019.…
WOSCOPS Trial Summary WOSCOPS trial was a double-blind, parallel-group, randomized, placebo-controlled trial that was designed to assess the benefit of pravastatin in reducing CV events…
WOEST Trial Summary: The WOEST trial was a multicenter, open-label, randomized, controlled clinical trial to assess if clopidogrel alone could reduce bleeding risk compared to…
WARFASA Trial Summary The WARFASA trial was a multicenter, double-blinded, randomized, placebo-controlled trial to assess whether aspirin could reduce the recurrence of venous thromboembolism (VTE)…